Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (380)	7/10/2003 12:22:18 PM
From: keokalani'nui	of 625

Abbott Laboratories (ABT:NYSE - news - commentary - research - analysis) said sales surged in the second quarter, helped by growth in U.S. pharmaceutical revenue and favorable foreign exchange rates, but overall profits fell after the company factored in one-time charges. Worldwide sales rose 9.5% to $4.72 billion from $4.32 billion in the second quarter of 2002. Sales in U.S. markets were $2.79 billion, up 7.2% from a year ago, and international sales climbed 12.9% to $1.93 billion. (snip) U.S. pharmaceutical sales rose 26.8% in the quarter, driven by strong growth of Depakote, Flomax, TriCor, Biaxin, Kaletra and Omnicef. Worldwide Humira sales totaled $57 million, including $54 million in the U.S. Abbott expects Humira sales to total more than $250 million in 2003. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next